$3.25
2.60% today
Nasdaq, Apr 03, 06:26 pm CET
ISIN
US53630X1046
Symbol
LPCN
Sector
Industry

Lipocine, Inc. Stock price

$3.17
+0.16 5.32% 1M
-1.08 25.41% 6M
-1.71 35.04% YTD
-1.80 36.22% 1Y
-18.59 85.43% 3Y
-3.99 55.71% 5Y
-109.54 97.19% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
-0.18 5.23%
ISIN
US53630X1046
Symbol
LPCN
Sector
Industry

Key metrics

Market capitalization $16.96m
Enterprise Value $-4.67m
P/E (TTM) P/E ratio 621.57
EV/FCF (TTM) EV/FCF 3.56
EV/Sales (TTM) EV/Sales -0.42
P/S ratio (TTM) P/S ratio 1.51
P/B ratio (TTM) P/B ratio 0.81
Revenue growth (TTM) Revenue growth 10,081.34%
Revenue (TTM) Revenue $11.20m
EBIT (operating result TTM) EBIT $-1.16m
Free Cash Flow (TTM) Free Cash Flow $-1.31m
Cash position $21.63m
EPS (TTM) EPS $0.01
P/E forward negative
P/S forward 11.28
EV/Sales forward negative
Short interest 1.59%
Show more

Is Lipocine, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Lipocine, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Lipocine, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Lipocine, Inc.:

Buy
100%

Financial data from Lipocine, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
11 11
10,082% 10,082%
100%
- Direct Costs 0.04 0.04
33% 33%
0%
11 11
13,850% 13,850%
100%
- Selling and Administrative Expenses 4.96 4.96
2% 2%
44%
- Research and Development Expense 7.31 7.31
28% 28%
65%
-1.11 -1.11
93% 93%
-10%
- Depreciation and Amortization 0.04 0.04
33% 33%
0%
EBIT (Operating Income) EBIT -1.16 -1.16
92% 92%
-10%
Net Profit 0.01 0.01
100% 100%
0%

In millions USD.

Don't miss a Thing! We will send you all news about Lipocine, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lipocine, Inc. Stock News

Neutral
PRNewsWire
8 days ago
48 hour at-home dosing Patient dosing expected in Q2/2025 SALT LAKE CITY , March 26, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics, today announced the initiation of a Phase 3 trial for LPCN 1154 (oral brexanolone) which is in development for the treatment of postpar...
Neutral
PRNewsWire
21 days ago
SALT LAKE CITY , March 13, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for the year ended December 31, 2024, and provided a corporate update. Oral Brexanolone LPCN 1154 is an oral formulation of the neuroactive steroid brexa...
Neutral
PRNewsWire
22 days ago
SALT LAKE CITY , March 12, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that the U.S. Food and Drug Administration (FDA) has recently informed sponsors of approved testosterone products about class-wide labeling changes. This decision follows ...
More Lipocine, Inc. News

Company Profile

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development for the delivery of drugs using proprietary delivery technology. The firm involves in applying oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. It offers TLANDO, an oral testosterone replacement therapy. The company was founded in 2011 and is headquartered in Salt Lake City, UT.

Head office United States
CEO Mahesh Patel
Employees 16
Founded 2011
Website www.lipocine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today